Cytek Biosciences, Inc. (CTKB) CEO Wenbin Jiang on Q2 2022 Results Earnings Call Transcript

Aug. 10, 2022 10:18 PM ETCytek Biosciences, Inc. (CTKB)
SA Transcripts profile picture
SA Transcripts

Cytek Biosciences, Inc. (NASDAQ:CTKB) Q2 2022 Earnings Conference Call August 10, 2022 5:00 PM ET

Company Participants

Paul Goodson - Head, IR

Wenbin Jiang - President, CEO and Chairman

Patrik Jeanmonod - CFO

Conference Call Participants

Max Masucci - Cowen & Company

Matt Sykes - Goldman Sachs

David Westenberg - Piper Sandler

Tejas Savant - Morgan Stanley


Good day and thank you for standing by. Welcome to the Cytek Biosciences' Second Quarter 2022 Earnings Conference Call. At this time, all participants are in a listen-only mode. After the speakers' presentation, there will be a question-and-answer session. [Operator Instructions] Please be advised that today's conference is being recorded.

I would now like to hand the conference over to your speaker today, Paul Goodson, Investor Relations. Please go ahead.

Paul Goodson

Thank you, operator. Earlier today, Cytek Biosciences released financial results for the quarter ended June 30th, 2022. If you haven't received this news release or if you'd like to be added to the company's distribution list, please send an e-mail to Joining me today from Cytek are Wenbin Jiang, CEO; and Patrik Jeanmonod, Chief Financial Officer.

Before we begin, I'd like to remind you that we will make statements during this call that are forward-looking statements within the meaning of the federal securities laws, including statements regarding Cytek's business plans, strategies, opportunities, and financial projections.

These statements are based on the company's current expectations and inherently involve significant risks and uncertainties that could cause actual results or events to materially differ from those anticipated. Additional information regarding these risks and uncertainties appears in the section entitled Forward-Looking Statements in the press release Cytek issued today and in Cytek filings with the SEC.

This call will also include a discussion of certain financial measures that are not calculated in accordance

Recommended For You


To ensure this doesn’t happen in the future, please enable Javascript and cookies in your browser.
Is this happening to you frequently? Please report it on our feedback forum.
If you have an ad-blocker enabled you may be blocked from proceeding. Please disable your ad-blocker and refresh.